Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Reports Surge in Net Income; Revenue, R&D Grows

NEW YORK, July 26 - Beckman Coulter today reported a 4-percent increase in second-quarter revenue, a nudge up in R&D spending, and a strong jump in net income.


For the period ended June 30, the life-sciences tool giant posted an increase in total revenues to just over $516 million from $496 million one year ago. Sales of its clinical diagnostic products inched up 6 percent year over year to $356 million, and sales of its automated genetic-analysis tools jumped 15 percent from the second quarter last year to $43.7 million, the company said.


R&D spending saw a slight increase, to $47.8 million from $47.3 million in the same period one year ago. Second quarter net income, meantime, grew 14 percent to $41.9 million, or $.64 per share, from $36.8 million, or $.58 per share, year over year, the company said.


Beckman Coulter said it had roughly $42.5 million in cash and equivalents as of June 30, 2002, compared with $36 million in the same period one year ago.


Click here for more information.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.